Key points are not available for this paper at this time.
Synthetic peptide analogues of sequences in the HER-2 protooncogene (HER-2) were selected based on the presence of HLA-A2.1 anchor motifs to identify the epitopes on HER-2 recognized by ovarian tumor-reactive CTL. 19 synthetic peptides were evaluated for recognition by four HLA-A2 ovarian-specific cytotoxic T lymphocyte (CTL) lines obtained from leukocytes associated with ovarian tumors. The nonapeptide E75 (HER-2, 369-377:KIFGSLAFL) was efficient in sensitizing T2 cells for lysis by all four CTL lines. This peptide was specifically recognized by cloned CD8+ CTL isolated from one of the ovarian-specific CTL lines. E75-pulsed T2 cells inhibited lysis by the same CTL clone of both an HLA-A2+ HER-2high ovarian tumor and a HER-2high cloned ovarian tumor line transfected with HLA-A2, suggesting that this or a structurally similar epitope may be specifically recognized by these CTL on ovarian tumors. Several other HER-2 peptides were recognized preferentially by one or two CTL lines, suggesting that both common and private HER-2 epitopes may be immunogenic in patients with ovarian tumors. Since HER-2 is a self-antigen, these peptides may be useful for understanding mechanisms of tumor recognition by T cells, immunological tolerance to tumor, and structural characterization of tumor antigens.
Building similarity graph...
Analyzing shared references across papers
Loading...
Bryan Fisk
Washington University in St. Louis
Tana Blevins
The University of Texas MD Anderson Cancer Center
J. Taylor Wharton
Gynecologic Oncology Group
The Journal of Experimental Medicine
The University of Texas MD Anderson Cancer Center
Building similarity graph...
Analyzing shared references across papers
Loading...
Fisk et al. (Thu,) studied this question.
synapsesocial.com/papers/6a158f699b87f33fc69fa9b8 — DOI: https://doi.org/10.1084/jem.181.6.2109
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: